EUVIMEDEUVIMED entdecken
LeitlinieOpen Access · CC BY 4.0

Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HER2+ Breast Cancer in Both the Early and Metastatic Settings (2025 Update)

Aalok Kumar, Katarzyna J Jerzak, Karen A Gelmon iD, Jean-François Boileau, Nathaniel Bouganim, Christine Brezden-Masley iD, Jeffrey Q Cao, David W Cescon iD, Stephen Chia, Scott Edwards, Anil Abraham Joy iD, Kara Laing und 6 weitere

Current Oncology · 31.03.2026 · 33 (4) · 200

DOI: 10.3390/curroncol33040200 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Current Oncology, online erschienen am 31.03.2026. Verfasst von Aalok Kumar und 17 weiteren Autor:innen. Beteiligte Einrichtung: BC Cancer-Surrey, University of British Columbia, Vancouver, BC V3V 1Z2, Canada. Hauptthemen laut MEDLINE: Breast Neoplasms, Erb-b2 Receptor Tyrosine Kinases. Die Arbeit nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Breast Cancer Canada, Diagnostics & Treatment Pillar from Breast Cancer Canada.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Human epidermal growth factor receptor 2-positive (HER2+) breast cancer is an aggressive subtype associated with a poor prognosis when not optimally treated. Over the past year, major advances—including results from DESTINY-Breast05, DESTINY-Breast09, DESTINY-Breast11, PATINA, and long-term APHINITY follow-up—have changed the treatment landscape regarding the place in therapy of antibody–drug conjugates and the optimal sequencing of systemic therapies. These developments prompted the need for updated evidence-informed consensus recommendations to support consistent, high-quality care across Canada. Research Excellence, Active Leadership Canadian Breast Cancer Alliance (REAL Alliance), comprising clinical-academic oncologists from across Canada and Breast Cancer Canada, updated its 2024 HER2+ recommendations through a modified Delphi process with up to three rounds of anonymous voting. Consensus was defined a priori as ≥75% agreement. This 2025 update incorporates new data in early-stage, metastatic, and central nervous system-involved disease, including revisions to neoadjuvant and adjuvant treatment pathways and expanded guidance on the clinical use of antibody–drug conjugates.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsErb-b2 Receptor Tyrosine KinasesFemaleHumansCanadaNeoplasm Metastasis

Stichwörter der Autor:innen

HER2+HER2-directed therapyHER2-positiveREAL Allianceantibody–drug conjugatebreast cancer

Substanzen

Erb-b2 Receptor Tyrosine KinasesERBB2 protein, human

Autor:innen und Institutionen

  • BC Cancer-Surrey, University of British Columbia, Vancouver, BC V3V 1Z2, Canada.
  • Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON M4N 3M5, Canada.
  • BC Cancer-Vancouver, University of British Columbia, Vancouver, BC V5Z 4E6, Canada.
  • Jewish General Hospital, McGill University, Montréal, QC H3T 1E2, Canada.
  • McGill University Health Centre, McGill University, Montréal, QC H4A 3J1, Canada.
  • Marvelle Koffler Breast Centre, Mount Sinai Hospital, University of Toronto, Toronto, ON M5G 1X5, Canada.

ORCID-Profile: Karen A Gelmon, Christine Brezden-Masley, David W Cescon, Anil Abraham Joy, Nathalie LeVasseur, Sandeep Sehdev, Christine Simmons, Mita Manna

Förderung

  • Breast Cancer Canada
  • Diagnostics & Treatment Pillar from Breast Cancer Canada

Zitieren

APA

Kumar, A., Jerzak, K. J., Gelmon, K. A., Boileau, J. F., Bouganim, N., Brezden-Masley, C., Cao, J. Q., Cescon, D. W., Chia, S., Edwards, S., Joy, A. A., Laing, K., LeVasseur, N., Sehdev, S., Simmons, C., Webster, M., Manna, M., & On Behalf Of Patient Advocacy Breast Cancer Canada (2026). Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HER2+ Breast Cancer in Both the Early and Metastatic Settings (2025 Update). Current Oncology, 33(4), 200. https://doi.org/10.3390/curroncol33040200

Vancouver

Kumar A, Jerzak KJ, Gelmon KA, Boileau JF, Bouganim N, Brezden-Masley C, et al. Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HER2+ Breast Cancer in Both the Early and Metastatic Settings (2025 Update). Current Oncology. 2026;33(4):200. doi:10.3390/curroncol33040200

BibTeX
@article{Kumar2026,
  author = {Kumar, Aalok and Jerzak, Katarzyna J and Gelmon, Karen A and Boileau, Jean-François and Bouganim, Nathaniel and Brezden-Masley, Christine and Cao, Jeffrey Q and Cescon, David W and Chia, Stephen and Edwards, Scott and Joy, Anil Abraham and Laing, Kara and LeVasseur, Nathalie and Sehdev, Sandeep and Simmons, Christine and Webster, Marc and Manna, Mita and On Behalf Of Patient Advocacy Breast Cancer Canada},
  title = {Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HER2+ Breast Cancer in Both the Early and Metastatic Settings (2025 Update)},
  journal = {Current Oncology},
  year = {2026},
  volume = {33},
  number = {4},
  pages = {200},
  doi = {10.3390/curroncol33040200}
}
Kostenlos starten →